newsfilter
← Latest News
GlobeNewswire·

ProKidney confirms Phase 3 program for autologous kidney cell therapy REACT®

WINSTON-SALEM, N.C., April 12, 2022 (GLOBE NEWSWIRE) -- ProKidney LP ("ProKidney"), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease ("CKD"), today announced the updated design for its REACT® Phase